Invivyd, Inc. (IVVD)
NASDAQ: IVVD · Real-Time Price · USD
1.380
-0.080 (-5.48%)
At close: Apr 28, 2026, 4:00 PM EDT
1.410
+0.030 (2.17%)
After-hours: Apr 28, 2026, 7:56 PM EDT
Invivyd Employees
Invivyd had 122 employees as of December 31, 2025. The number of employees increased by 22 or 22.00% compared to the previous year.
Employees
122
Change (1Y)
22
Growth (1Y)
22.00%
Revenue / Employee
$437,918
Profits / Employee
-$430,238
Market Cap
390.27M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 122 | 22 | 22.00% |
| Dec 31, 2024 | 100 | 5 | 5.26% |
| Dec 31, 2023 | 95 | 9 | 10.47% |
| Dec 31, 2022 | 86 | -17 | -16.50% |
| Dec 31, 2021 | 103 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| Ginkgo Bioworks Holdings | 485 |
| Neurogene | 131 |
| Niagen Bioscience | 117 |
| Neumora Therapeutics | 96 |
| Century Therapeutics | 78 |
| Lexeo Therapeutics | 59 |
| Atea Pharmaceuticals | 55 |
IVVD News
- 8 days ago - Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit - GlobeNewsWire
- 19 days ago - Invivyd Stock Surges As FDA Alignment Boosts COVID-19 Program - Benzinga
- 19 days ago - Invivyd Transcript: Study update - Transcripts
- 19 days ago - Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles - GlobeNewsWire
- 22 days ago - Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Invivyd Announces Presentation at the World Vaccine Congress Washington - GlobeNewsWire
- 7 weeks ago - Invivyd Earnings Call Transcript: Q4 2025 - Transcripts
- 7 weeks ago - Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates - GlobeNewsWire